Navigation Links
Avidity Biosciences Announces Publication on Targeting Therapeutic Oligonucleotides by Arthur A. Levin in the New England Journal of Medicine
Date:1/5/2017

LA JOLLA, Calif., Jan. 4, 2017 /PRNewswire/ -- Avidity Biosciences LLC, a biotechnology company advancing Antibody-siRNA Conjugates (ASCs) as a new class of precision medicines, today announced a publication entitled, "Targeting Therapeutic Oligonucleotides," in the January 5, 2017 issue of the New England Journal of Medicine.1 The publication, authored by Arthur A. Levin, Ph.D., executive vice president of research and development, appears in the Clinical Implications of Basic Research section.

In the publication, Dr. Levin summarizes the advantages of targeted strategies for the delivery of therapeutic oligonucleotides. 

"Recent work indicates that the usefulness of therapeutic oligonucleotides can be increased by conjugating oligonucleotides with targeting moieties so that they home to specific cell types," said Dr. Levin. "Targeted delivery was determined to result in a median effective dose that was one thirtieth of that associated with non-targeted delivery, which clearly underscored the potential advantage of the approach."

Levin continues, "There remains a need to target non-hepatic cells specifically and efficiently: a means to achieve this goal could lie in the exploitation of the natural heterogeneity of cell surface receptors."

Dr. Levin has an unparalleled track record and reputation in the field of nucleic acid-based therapeutics. Prior to his role at Avidity Biosciences, he held senior drug development roles at miRagen Therapeutics, Ionis Pharmaceuticals and Santaris Pharma. He has played key roles in the development of numerous oligonucleotides, including the first approved antisense NDAs and the first microRNA-targeted therapeutic in clinical trials. He has a combined three decades of experience in all aspects of drug development from discovery through drug registration, both in large pharma and biotech companies. Dr. Levin has published over 60 scientific articles and has several of the most cited reviews in the field. He serves as a director of the Oligonucleotide Therapeutics Society and holds several additional scientific organization affiliations and honors. He received a doctorate in toxicology from the University of Rochester and a bachelor's degree in biology from Muhlenberg College.

About Avidity Biosciences

Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASCs) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics. Avidity is collaborating with partners to discover and develop best-in-class drug candidates against important undrugged therapeutic targets. The company has entered research collaborations with leading biopharma companies and is actively seeking additional partnerships. Avidity has raised $25 million in venture financing from a top-tier group of sophisticated healthcare investors.  More information about Avidity Biosciences can be found on the company's website at www.aviditybiosciences.com.

1  Levin, A, Targeting therapeutic oligonucleotides. N Engl J Med 2016;376: 86-88.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avidity-biosciences-announces-publication-on-targeting-therapeutic-oligonucleotides-by-arthur-a-levin-in-the-new-england-journal-of-medicine-300385825.html


'/>"/>
SOURCE Avidity Biosciences
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Biotech Stocks on Investors Radar -- Eleven Biotherapeutics, Illumina, Sangamo Biosciences, and CytRx
2. Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down
3. DuPont Industrial Biosciences to Begin New Research Aimed to Enable Global Access for Protein Medications
4. Roche announces termination of 2013 Development, Commercialization and License Agreement with Pacific Biosciences
5. ACEA Biosciences Presents Efficacy and Safety Data From AC0010 Phase I/II Clinical Trial for Treatment of Advanced Non-Small Cell Lung Cancer at the WCLC 2016 Conference
6. ACEA Biosciences Announces Data Presentation at WCLC 2016 Conference: New AC0010 Data to Be Presented
7. Vigene Biosciences Acquires the cGMP Manufacturing Facility and Assets of Omnia Biosciences
8. ACEA Biosciences Appoints Li Xu, M.D. as Chief Medical Officer
9. DuPont Industrial Biosciences and MIAVIT Announce Supply Agreement for Biogas Enzymes
10. Agro BioSciences Expands Probiotic Strain Portfolio
11. ARMO BioSciences Immunotherapy AM0010 Receives Orphan Drug and Fast Track Designations from the U.S. FDA for the Treatment of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2019)... ... ... Locus Agricultural Solutions (Locus AG) reports record levels of carbon sequestered in ... ® , which is pulling up to 121% more carbon into the soil than ... from the treatment of almonds, cherries, turf/sod, grapes and citrus across the U.S., as ...
(Date:8/6/2019)... ... August 05, 2019 , ... Advanced ... recognized as a distinguished leader by PharmaVOICE magazine, earning him a prestigious spot ... the magazine’s July/August special issue. , As the executive vice president of business ...
(Date:7/30/2019)... ... July 30, 2019 , ... The ... and cooking events company. Not only has the company already hosted many of ... Private Cooking Parties to its guests. , With Lajollacooks4u’s Private Cooking Parties, guests ...
(Date:7/19/2019)... ... 18, 2019 , ... Global precision motion and piezo technology ... motion facilities in Lederhose, Germany, increasing their current footprint by half again. , ... in addition to general office space, a significant increase to its existing 129,000ft² ...
Breaking Biology Technology:
(Date:8/1/2019)... (PRWEB) , ... August 01, 2019 , ... John R. ... Johannes Fruehauf, MD, PhD, founder and president of BioLabs, which provides premier co-working spaces ... CFO role to strengthen our ability to forecast and manage growth,” says Fruehauf. “BioLabs ...
(Date:8/1/2019)... ... 31, 2019 , ... Molecular Devices, LLC, a leader in ... of its FLIPR® Penta High-Throughput Cellular Screening System. , The new FLIPR Penta ... G-protein-coupled receptors (GPCRs) and ion channels, offering a new high-speed camera option capable ...
(Date:8/1/2019)... ... 2019 , ... USDM Life Sciences (USDM) announces that Jay Crowley, Vice President ... addressing challenges with the upcoming EU MDR IVDR regulations . , ... variety of positions over his 26 years at the FDA, including developing the framework ...
Breaking Biology News(10 mins):